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Abstract: When surgical ligation of bleeding fails, or is not possible, surgeons rely on a   number 
of hemostatic aids, including thrombin. This review discusses the history, pharmacology and 
clinical application of thrombin as a surgical hemostat. The initial thrombin was bovine in 
origin, but its use has been complicated by the formation of antibodies that cross-react with 
human coagulation factors. This has been associated with life-threatening bleeding and in some 
circumstances anaphylaxis and death. Human thrombin, isolated from pooled plasma of donors, 
was developed in an effort to minimize these risks, but its downsides are its limited availability 
and the potential for transmitting blood-borne pathogens. Recently a recombinant thrombin has 
been developed, and approved for use by the FDA. It has the advantage of being minimally 
antigenic and devoid of the risk of viral transmission. Thrombin is often used in conjunction 
with other hemostatic aids, including absorbable agents such as Gelfoam, and with fibrinogen 
in fibrin glues. The last part of this review will discuss these agents in detail, and review their 
clinical applications.
Keywords: bovine, recombinant, human, thrombin, antigenicity, antibodies, food drug 
  administration (FDA)
Introduction
In any surgical procedure, hemostasis is vital to success. When surgical ligation of 
bleeding vessels or electrocautery of smaller vessels fails, or is not possible, surgeons 
rely on a number of hemostatic aids: one such hemostatic ancillary is thrombin.
Thrombin has a long history as a vehicle to affect hemostasis. Descriptions can be 
found in the European literature as early as 1892 for the use of thrombin.1 Early on, 
thrombin was used by barbers and boxers, for hemostasis of shaving cuts and fight 
lacerations. Thrombin has been purified from numerous sources and used as a   clinical 
aid for topical hemostasis for more than 60 years. Records citing thrombin use in 
surgery date back to the 1940s. Since then its use has grown exponentially, and now 
thrombin is used in more than 1 million patients in the United States each year at a cost 
of 250 million dollars.2 Over the past few years, there have been new developments in 
thrombin, namely human thrombin, and FDA approval of recombinant thrombin.3,4
This review will discuss the mechanism by which thrombin acts, the history of 
bovine thrombin, the development of human thrombin, methods of thrombin delivery 
in clinical applications, and finally the future of thrombin in regards to recombinant 
technologies.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Mechanism of thrombin
Thrombin has a number of well-studied biological activities, 
which serve to achieve coagulation and hemostasis. With 
tissue injury and bleeding, exposed collagen and released 
tissue factor cause activation of the intrinsic and extrinsic 
coagulation pathways. Both pathways lead to activation of 
factor X which along with activated factor V forms a complex 
that cleaves the prothrombin protein into the active thrombin 
molecule. Thrombin production is the final coagulation step 
required to cleave fibrinogen into fibrin which provides a 
hemostatic lattice for platelet aggregation and thrombus 
formation at the site of injury (Figure 1).
In addition to the coagulation cascade, thrombin can act 
directly on a number of cell types. At the smooth muscle 
cell, it causes vasoconstriction which aids in hemostasis. By 
activating platelets it promotes their aggregation at the site 
of thrombus. Activated thrombin also acts as a mitogen and 
chemoattractant for neutrophils and fibroblasts, and even 
induces the formation of vascular endothelial growth factor 
(VEGF) for tissue and vascular remodeling and repair.1,2,5
Interestingly, thrombin not only promotes coagulation, 
but can also activate the anticoagulant system through 
protein C. When there is vascular injury the   procoagulant 
effects of thrombin are activated as described above. 
However, when there is no vascular disruption, thrombin 
will interact with thrombomodulin to activate protein C to 
improve   circulation through an anticoagulant effect.6
Through all of these varied actions, thrombin promotes 
and modulates coagulation. For the purpose of this treatise 
we will confine the discussion to its prothrombotic role and 
how that has been harnessed to limit bleeding in a variety 
of surgical procedures.
Bovine thrombin
The initial source of thrombin was from a bovine origin 
and its effectiveness at facilitating surgical hemostasis 
resulted in it quickly becoming a popular surgical   ancillary. 
With increased usage and thus patient exposure, isolated 
case reports surfaced suggesting that bovine thrombin may 
be operational in surgically-related bleeding   abnormalities. 
The first report in the literature questioning bovine thrombin 
safety was in 1989 by Flaherty et al.7 They identified four 
patients with prior bovine thrombin exposure and unex-
plained prolonged thrombin times (greater than 300 seconds). 
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Figure 1 Diagram of coagulation cascade. Blue boxes and arrows include various hemostatic agents with their mechanism of actions. (*) these agents affect the entire 
coagulation cascade by concentration and by creating a matrix for coagulation factors at the bleeding site. Red arrows indicate the inhibition caused by bovine generated 
antibodies to thrombin, factor v, and platelet antiphospholipids.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
137
Thrombin use in surgery: a review
Mixing studies suggested the presence of an inhibitor, and 
the thrombin test times were able to be corrected if human 
thrombin was substituted for bovine thrombin in the test 
reagents. The antibodies to bovine thrombin were isolated 
from the patients, and found to prolong the thrombin times 
if added to the plasma of normal patients.
The actual antibody generated by bovine thrombin 
exposure was further characterized by Zehnder in 1990.8 
He reported a 65-year-old patient who underwent a cardiac 
procedure complicated by uncontrolled and persistent post-
operative bleeding. The patient’s factor V activity was 1% 
of normal and was not corrected by mixing with normal 
plasma, demonstrating the presence of an inhibitor against 
factor V. This inhibitor was found to be an antibody of 
bovine factor V that cross-reacted with the patient’s own 
factor V (Figure 1). The source of the bovine factor V was 
from the bovine thrombin preparation which contained not 
only thrombin, but other bovine plasma proteins. Similar 
case reports soon surfaced documenting coagulopathy that 
was associated with bovine thrombin exposure. Additional 
bovine thrombin antibodies have been isolated, including 
antibodies to the bovine thrombin itself.9,10
In 1994, Ortel reported a case series of four patients 
with acquired factor V inhibitors from presumed repeated 
exposure to bovine thrombin preparations. The authors 
reviewed the literature and identified an additional thirteen 
patients with documented bovine thrombin preparation 
induced factor V antibodies. They noted that even though 
all seventeen patients had the factor V inhibitor, each patient 
had a different clinical course ranging from asymptomatic 
to life threatening hemorrhage.11 Despite the accumulating 
data concerning factor V antibody generation, the commer-
cial use of bovine thrombin continued and in fact increased. 
However by 1996 the weight of the evidence resulted in the 
FDA attaching a Black Box drug warning label to all bovine 
thrombin containing products.2
In addition to hemorrhage, case reports of thrombotic 
reactions to antibodies generated by bovine thrombin prepa-
rations began to surface. In a study with eighty-eight hemo-
dialysis patients12 and another case report with one cardiac 
patient13 the authors demonstrated certain patients exposed 
to bovine thrombin preparations developed antiphospholipid 
antibodies causing subsequent thrombosis. More bovine 
thrombin induced antibodies continued to be discovered, 
as mice experiments by Schoenecker et al in 2001 demon-
strated autoantibodies similar to those found in autoimmune 
disorders like systemic lupus erythematosus ( SLE) could be 
caused by bovine thrombin exposure.14
To better delineate the incidence of antibody formation 
following bovine thrombin exposure, Ortel in 2001 
  prospectively studied 151 patients undergoing cardiac 
surgery. The authors found more than 95% of patients 
developed a   seropositive response to bovine coagulation 
proteins, and 51% manifested elevated antibody levels to 
the corresponding human coagulation proteins after bovine 
thrombin exposure. Furthermore, 15 of these 151 patients 
had had previous surgeries and were positive for preoperative 
antibodies to bovine proteins from assumed previous 
thrombin exposure. These 15 had significantly more adverse 
effects (73.3%) when compared to those without previous 
surgery or antibodies (33.8%, P-0.0042).15
In 2002, another review by Streiff documented one 
hundred and twenty-six cases of factor V inhibitors found 
in the medical literature. These cases included patients with 
spontaneous and bovine thrombin induced factor V inhibitors. 
Interestingly a majority of the cases had been found in the 
previous ten years indicating an increasing incidence. Fifty-
eight of the patients were bovine thrombin induced only, and 
33% developed some sort of bleeding complication.16
Almost every surgical specialty has had a case study or 
series of adverse events related to the use of bovine thrombin: 
neurosurgery,17–19 pediatric surgery,20–23 cardiac surgery,18,24,25 
ob-gyn,26 vascular,27,28 and nephrology.29 Despite this evi-
dence bovine thrombin continued to be widely used, with 
reported market growth to $247 million in 2007.30 The major 
reason for the continued popularity of bovine thrombin was 
the lack of an alternative thrombin preparation. However, 
human thrombin and more recently a recombinant thrombin 
are now available, with new evidence showing a safer profile 
and less immunogenic reactivity with recombinant thrombin 
in particular. These products show promise in the surgical 
ancillary market.
Human thrombin
The adverse immunological effects associated with bovine 
thrombin have lead to the development of thrombin from 
alternative sources. Human derived thrombin is one such 
alternative. Human thrombin is isolated from pooled human 
plasma donors at United States (US) licensed collection 
centers. All donors are tested for blood-borne diseases (HIV , 
hepatitis, parvovirus B19). The plasma is then processed 
through a series of separation and filtration steps followed by 
incubation of the solution with calcium chloride to isolate and 
activate prothrombin to thrombin. The solution subsequently 
undergoes ultrafiltration, vapor heat treatment, solvent-
detergent treatment, sterile filtration and freeze-drying.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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The vapor heat and solvent-detergent treatment steps used 
in the manufacturing process have been shown to be capable 
of significant viral reduction. No procedure, however, has 
been shown to be completely effective in removing viral 
infectivity from derivatives of human plasma. Therefore 
although relatively safe, there is still no assurance that human 
thrombin is completely free of blood-borne pathogens.31–34 
An additional issue is the finite availability of human-derived 
blood products and whether the supply can be sufficient for 
the potential demand.
In 2007, the FDA finally approved the first stand-alone 
human thrombin preparation, Evithrom® (OMRIX Biophar-
maceuticals Ltd, New York, New York, USA).35 (US Food 
and Drug Administration 2007). Previously, human throm-
bin was only used in FDA-approved combination products, 
namely Floseal® (Baxter; Deerfield, IL, USA), and the fibrin 
glues (to be discussed in greater detail later).
Results from a published clinical trial of Evithrom ver-
sus bovine thrombin can be found in the packet insert for 
Evithrom. In this phase III, prospective, randomized, con-
trolled, double-blinded study of 305 subjects at 22   centers 
in the US, subjects undergoing elective cardiovascular, 
neurological (spinal) or general surgical procedures were 
randomized to treat oozing or bleeding (of mild intensity 
that could not be controlled by other surgical techniques) 
with bovine thrombin and   Surgifoam® (Johnson and Johnson 
Wound Management, Somerville, NJ, USA); or Evithrom 
and Surgifoam. Treatment with Evithrom was as successful 
as treatment with bovine thrombin in achieving the primary 
efficacy endpoint: hemostasis within 10   minutes of product 
application. The secondary efficacy endpoint of hemostasis 
within 6 and 3 minutes of product application also was 
achieved. In terms of safety, there was no difference between 
the two groups.
Nearly all patients experienced one or more adverse 
events (99.7%), with the majority being laboratory abnor-
malities in both groups. In the Evithrom group 17% had 
serious adverse events as compared to 11% in the bovine 
thrombin group. Two subjects (1.3%) in the Evithrom group 
experienced a severe adverse event: respiratory arrest and 
post-procedural hematoma in one subject and an extradural 
hematoma in the other. Two (1.3%) subjects in the bovine 
thrombin group experienced severe adverse events: pyrexia 
and post-procedural hematoma. Twelve percent who experi-
enced one or more adverse events were considered possibly, 
probably, or definitely related to the study drugs. No deaths 
were reported during the study period.36 Limitations of the 
study which, to the author’s credit, are detailed in the article, 
include the lack of a placebo-control group, the potential for 
intersurgeon variability, and the fact that antibody assessment 
was not evaluable in all patients.
Recombinant human thrombin 
(rThrombin)
The development of a recombinant human thrombin, 
  Recothrom® (Zymogenetics, Inc, Seattle, Washington, 
USA), provides a manufactured source of thrombin that 
is devoid of the risks of antibody development found with 
bovine thrombin or the theoretic risks of viral transmission 
with human-derived thrombin. Recombinant thrombin has 
the identical amino acid sequence to human thrombin, and 
its precursors are made from a genetically-modified Chinese 
hamster ovary cell line. Enzymes derived from snake venom 
are used to activate the precursors to human thrombin. 
Although, hypothetically, Recothrom is free from infectious 
agents, there is still a final purification process with solvent-
detergent treatment and nanofiltration. This product has been 
approved by the US FDA since January 2008.3,4
Preclinical studies demonstrated rThrombin to be safe in 
animal subjects.33 Phase 2 trials have been completed compar-
ing the safety profile of rThrombin to placebo. One hundred 
and thirty patients undergoing AV graft, liver resections, 
peripheral artery bypass, or spinal surgery were random-
ized to either rThrombin or placebo soaked in   Gelfoam® 
  (Pharmacia & Upjohn, Bridgewater, NJ, USA) or   Surgifoam. 
No   patterns of treatment-related adverse events were associ-
ated with rThrombin. Recombinant thrombin induced minimal 
antibody generation and no antibody-  mediated   reactions to 
coagulation proteins were documented.37
A phase 3 trial compared the efficacy, safety, and 
antigenicity of rThrombin versus bovine thrombin. Four 
hundred and one patients undergoing liver resection, spine, 
peripheral arterial bypass, or dialysis access surgery were 
randomly assigned to either rThrombin or bovine thrombin 
(bThrombin) for surgical hemostasis. A gelatin sponge was 
used as a carrier. Hemostasis was achieved at the time-to-
hemostasis evaluation site within 10 minutes in 95% of 
patients in each treatment group. Overall complications, 
including operative mortality, adverse events, and laboratory 
abnormalities, were similar between groups. However, in 
terms of antigenicity, 21.5% of the patients receiving bovine 
thrombin developed antibodies to the product whereas 
only 1.5% in the rThrombin group developed antibodies to 
rThrombin, P , 0.0001.
In post hoc analysis, those that developed anti-bThrombin 
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bleeding, thromboembolic events, hypersensitivity, and 
abnormal activated partial thromboplastin time (aPTT) as 
compared to those in the bThrombin group that did not 
develop antibodies (n = 157). This increase was not seen in 
those with anti-rThrombin antibodies (n = 3) as compared to 
those in the rThrombin group that did not develop   antibodies 
(n = 198).38
The companion study for the vascular subgroup in the 
previously mentioned phase 3 trial showed that adverse 
events were similar between the two thrombins in this sub-
group. In patients undergoing vascular surgery, rThrombin 
demonstrated a superior immunogenicity profile versus 
bThrombin. Moreover, a significantly greater proportion 
of patients receiving rThrombin achieved hemostasis at 
3 minutes compared with bThrombin (55% versus 39%, 
P , 0.05).39
Pooled results from a recently-published analysis from 
8 clinical trials further show compelling evidence of the 
safety and the low immunogenicity of rThrombin. Data from 
8 clinical trials, including the three mentioned above, were 
used to evaluate the safety and immunogenicity observations 
of rThrombin. Collectively, these trials included patients 
undergoing spinal procedures, major hepatic resections, 
creation of arterivenous grafts for hemodialysis access, 
peripheral arterial bypass procedures, and skin grafting for 
burn wounds. Adverse events and laboratory parameters 
were monitored until 29 days after the procedures. Immu-
nogenicity was evaluated on plasma samples collected at 
baseline and on day 29. Of the 583 patients who were treated 
with rThrombin, 5 (0.9%) patients developed antibodies to 
rThrombin 29 days after surgery, and these antibodies did 
not neutralize the biologic activity of native human thrombin 
(immunologic data only available for 552 patients). Adverse 
events reported for $10% of patients included incisional site 
pain, procedural pain, nausea, constipation, pyrexia, anemia, 
insomnia, vomiting, and pruritis. The reported adverse events 
were generally consistent with postprocedural events that are 
usually reported for patients undergoing surgery. Twelve 
(2.2%) patients with no previous exposure to rThrombin had 
pre-existing antibodies to rThrombin, however their antibody 
titers did not increase $10-fold at day 29. The collective 
results from this analysis demonstrate that rThrombin is 
well tolerated as a topical hemostatic agent in many surgical 
settings, and the data further contributes to the evidence of 
its safety and low immunogenic reactivity.40
Similar safety and immunogenic reactivity data seen in 
the above surgical patients were also seen in patients under-
going skin grafting for burns. This phase 2, multicenter, 
open-label study was of 72 patients with burn wounds who 
underwent partial or full-thickness autologous skin grafting. 
Patients received a spray application of rThrombin once every 
5 minutes for up to 20 minutes. Of 62 patients for whom data 
was available, 1 patient (1.6%) developed anti-rThrombin 
antibodies at day 29. One other patient had pre-existing 
antibodies to rThrombin, however neither of these antibodies 
to rThrombin neutralized native human thrombin. Adverse 
events occurred in the majority of patients, however all were 
typical sequelae of skin grafting.41
One safety issue that has been raised is the question of 
whether rThrombin would be safe to use in patients who have 
received other forms of thrombin, such as bovine thrombin, in 
the past. There is a suggestion that the antibodies formed in 
those with prior exposure to bovine thrombin may cross-react 
with rThrombin.42 A recent phase 3b, open-label, single-group 
study addressed this issue by evaluating the immunogenicity 
and safety of rThrombin in 209 vascular and spinal operation 
patients at high risk for pre-existing anti-bovine thrombin 
antibodies, who received rThrombin as a topical hemostat. 
Immunogenicity data were collected at baseline and approxi-
mately 1 month after the operation. Of the 200 patients with 
complete immunogenicity data, 31 (15.5%) had pre-existing 
anti-bovine thrombin antibodies, and 4 (2%) had pre-existing 
anti-rThrombin antibodies. None of the 200 patients devel-
oped new antibodies against rThrombin on day 29 (defined as 
$10-fold increase in titer). The reported adverse events were 
generally as expected for a surgical population and seemed 
similar for patients with or without pre-existing anti-bovine 
thrombin antibodies. The results of this study shed light on 
the issue of the potential cross-reactivity of pre-existing anti-
bovine antibodies with patients treated with rThrombin. It 
provides evidence that the use of topical rThrombin is well 
tolerated in patients with or without pre-existing antibodies 
to bovine thrombin, and is safe in these patients undergoing 
vascular or spinal operations.43
Mechanisms of delivery
Thrombin is used predominantly as a topical agent for 
  bleeding that cannot be controlled with suture ligation or 
electrocautery. It is particularly useful in neurosurgical 
applications near the spine, in liver surgery where there is 
raw liver surface bleeding, and in vascular surgery where 
needle holes in polytetrafluoroethylene (PTFE) grafts 
  continue to ooze.
There are many ways thrombin is used during a surgi-
cal procedure to effect hemostasis. It can be used alone, in 
combination with an absorbable hemostatic carrier, or in a Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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manufactured combination with fibrin. Given the previous 
discussion, it is important to know the source of thrombin 
(bovine, human, recombinant), and the source of any other 
additives in the manufactured preparations.
Thrombin used alone
In the past pure thrombin was only available from a 
bovine source, and manufactured as thrombin-JMI® 
(King   Pharmaceuticals, Inc, Bristol, TN, USA). Now there is 
also human thrombin (Evithrom) and recently, a recombinant 
thrombin (Recothrom).
Thrombin-JMI and Recothrom are stored at room tem-
perature, as a powder, which is reconstituted with saline into 
solution for use.44,45 Evithrom is packaged as a solution, and 
stored in a freezer. Otherwise it can be refrigerated for up 
to 30 days, or kept at room temperature for up to 24 hours.34 
All stand alone thrombins, regardless of origin, are applied 
as a solution and can be cumbersome for topical application 
unless sprayed into a mist, or used with another carrier (like 
the absorbable hemostatic agents) or in combination with 
fibrinogen to create a ‘glue’.
Thrombin combined with an inert carrier
Gelatin sponges are absorbable hemostatic agents that can 
be used alone or in combination with thrombin. Surgical 
use of gelatin sponges were first introduced in the 1940s for 
neurosurgical procedures. The gelatin consists of a purified 
pork or bovine skin. Its surface causes activation of the 
intrinsic coagulation pathway but its main effect is its ability 
to absorb approximately 45 times its weight, expanding to 
approximately 200% of its initial volume (Figure 1 (*)). This 
facilitates a concentration of coagulation factors at the site 
of bleeding. A number of manufactured versions exist, and 
it is available as a sheet, powder, prepackaged in a syringe, 
or even prepackaged with thrombin.
Gelfoam® (Pharmacia & Upjohn, Bridgewater, NJ, 
USA) comes in sheets, Surgifoam is also a sheet or powder, 
and Surgiflo® (Johnson and Johnson Wound Management, 
Somerville, NJ, USA) is available in an applicator syringe 
that allows for the addition of any thrombin solution. All these 
products carry a theoretic risk for antigenicity given they 
are derived from nonhuman sources, but to date no adverse 
events have been linked to gelatin formulations.
One issue with these agents is that their porous nature 
can cause expansion. In closed spaces like the spinal canal, 
cases have been reported where this expansion led to spinal 
cord compression injuries.46 In addition, there is also the pos-
sible risk of embolization if applied to open arterial bleeding 
rather than diffuse oozing. However, these risks are low and 
the user-friendly nature of the absorbable hemostatic agents 
makes them popular surgical ancillaries which are widely 
and frequently used by most surgical specialties.
Floseal is a prepackaged gelatin matrix with a separate 
human thrombin component. This human thrombin is a 
powder that is reconstituted with a calcium chloride solu-
tion then mixed with the gelatin matrix in a delivery syringe. 
Initially, both the gelatin and thrombin were from bovine 
origin, but in 2002 Baxter replaced the bovine thrombin 
with pooled human plasma thrombin. The gelatin matrix 
contains microgranules cross-linked with glutaraldehyde and 
human thrombin. Its action requires blood as the source of 
fibrinogen, on which contact, the gelatin granules expand to 
produce a tamponade-effect.47
Thrombin and fibrinogen (fibrin glue)
Fibrin glues contain thrombin and fibrinogen. When com-
bined the fibrinogen is activated by thrombin and converted 
into fibrin monomers. This forms an adhesive glue at the 
tissues applied. The fibrin monomers go on to interact with 
the patient’s own factor XIII and calcium to convert the 
final product into a fibrin polymer that allows for platelet 
activation and aggregation with subsequent hemostasis 
(Figure 1).
Fibrin glues come packaged with a dual chamber syringe 
that allows for the combination of the thrombin and fibrino-
gen after the plunger is depressed. Commercially available 
products include Tisseel® (Baxter; Deerfield, IL, US) and 
Evicel® (Johnson and Johnson Wound Management). All 
components in Evicel (formerly Crosseal®) are human 
derived. Tisseel uses thrombin and fibrinogen derived from 
human sources, but there is an additional fibrinolysis inhibi-
tor added to the fibrinogen component to prevent premature 
fibrinolysis after the fibrin glue is applied. This fibrinolysis 
inhibitor was originally extracted from bovine source mate-
rial, but in 2007 this was replaced with a synthetic inhibitor, 
rendering Tisseel bovine free.32
indications for use
All the above combination products are effective and none 
has demonstrated singular superiority with the exception of 
a few specific surgical settings. Currently, bovine thrombin 
is the most common thrombin used alone or in combination 
with a gelatin sponge. Manufactured combination products 
such as the fibrin glues and Floseal contain almost exclusively 
human thrombin. Recombinant thrombin which was just 
recently approved may replace bovine or human thrombin Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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in many of these applications, but to what degree remains 
to be seen.
For any given surgical procedure, it is mainly dependent 
on surgeon preference which thrombin or combination prod-
uct is used. In general, the stand-alone thrombin spray is used 
to assist in hemostasis of large, raw surface areas such as in 
the case of solid viscera injury and resection of retroperitoneal 
tumors. Gelatin/thrombin combinations are very helpful in 
achieving hemostasis in vascular and spinal procedures and 
the fibrin glues are most commonly used in reoperative cardiac 
procedures which are complicated by persistent and difficult to 
control mediastinal bleeding. The effectiveness of the gelatin/
thrombin combination to achieve hemostasis has been exten-
sively studied and they have been found to be quite effective. 
The different fibrin glues have also been studied in numerous 
surgical settings including liver resections,48 vascular PTFE 
grafts,49,50 and even inguinal hernia repairs.51
Conclusion
Thrombin has had a long history in surgical hemostasis, and 
has proven to be a useful and effective ancillary for surgical 
hemostasis. Early bovine thrombin formulations have been 
conclusively linked to the development of antibodies that 
cross-react with multiple human coagulation proteins, factor 
V being the most important. These bovine-induced antibod-
ies to human coagulation factors have led to numerous cases 
of life threatening bleeding and other complications. The 
development of human thrombin has provided an alterna-
tive to bovine thrombin, but it has the theoretic risk of viral 
transmission. The recent development and FDA approval of 
a recombinant protein thrombin product provides yet another 
potential alternative, with equal efficacy to bovine thrombin, 
without the attendant risk of antigenicity.38
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